Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.
Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.
Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.
By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.
Cerus Corporation (CERS) will release its first quarter 2023 financial results on May 4, 2023, after market close. A conference call and webcast will follow at 4:30 P.M. ET for management to discuss results and provide an outlook.
The company focuses on safeguarding the global blood supply with its INTERCEPT Blood System, which is the only pathogen reduction system approved by both CE and FDA for platelets and plasma. The red blood cell system is under review in Europe and in late-stage clinical development in the US. Additionally, the INTERCEPT system for Cryoprecipitation is approved in the US for producing therapeutic products addressing bleeding issues related to fibrinogen deficiency.
Cerus Corporation (Nasdaq: CERS) reported strong fourth quarter 2022 revenue of $51.3 million, a 2% increase year-over-year, with product revenue rising 10% to $44.0 million. Full-year 2022 product revenue reached $162.0 million, up 24% from 2021. Despite a dip in government contract revenue by 29% in Q4, the company reiterated its 2023 product revenue guidance of $165-170 million. Product gross profit hit a record high of $24.5 million, reflecting a margin of 55.7%. Operational expenses rose by 11% in Q4 to $41.8 million, while the net loss for Q4 was $13.6 million. As of December 31, 2022, Cerus had $102.2 million in cash and equivalents.
Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full year 2022 financial results on February 28, 2023, after market close. A conference call is scheduled for 4:30 PM ET that same day, where management will discuss the results and provide a business outlook. The live webcast can be accessed via the Investor Relations page on the Cerus website. A replay will be available approximately three hours post-call until March 14, 2023. Cerus is focused on ensuring the safety of the global blood supply, offering advanced technologies like the INTERCEPT Blood System.
Cerus Corporation (CERS) announced its participation in two upcoming investor conferences. CEO William ‘Obi’ Greenman will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14-15. He, along with CFO Kevin Green, will partake in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8 at 1:30 PM EST, with a live webcast available at this link. Cerus, based in Concord, California, is focused on securing the global blood supply, offering the only pathogen-reduction system for platelets and plasma with CE mark and FDA approval.
Cerus Corporation reported preliminary product revenues for Q4 2022 of
Cerus Corporation (NASDAQ: CERS) announced that its COO, Vivek Jayaraman, will participate in two upcoming conferences. He is scheduled to present at the Stifel 2022 Healthcare Conference on November 16 at 1:50 p.m. EST in New York and at the Stephens Annual Investment Conference on November 17 at 12:00 p.m. EST in Nashville, TN. To access the webcasts, visit ir.cerus.com. Cerus is focused on ensuring the safety of the global blood supply with its INTERCEPT Blood System, already approved in various regions.
Cerus Corporation (CERS) reported third quarter 2022 total revenue of $46.3 million, a 10% year-over-year increase, driven by $39.6 million in product revenue. Despite a 6% foreign exchange headwind, product gross profit rose to $21.9 million, with a gross margin of 55.4%. The net loss narrowed to $8.5 million or $0.05 per share. Cerus has secured a $9.1 million contract with the DoD for trauma treatment development and expects full-year product revenue guidance between $160 million and $162 million.
Cerus Corporation has been awarded a
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is Cerus Corporation's main focus?
What pathogens does the INTERCEPT Blood System target?
Where is the INTERCEPT Blood System marketed?
What products does Cerus Corporation offer?
What are some recent achievements of Cerus Corporation?
How does the INTERCEPT Blood System work?
What financial strategies does Cerus Corporation employ?
Is Cerus Corporation involved in research for emerging pathogens?
What regions are key markets for Cerus Corporation?
What segment does Cerus Corporation operate in?
